US20170296695A1 - Peptide having zirconia-binding capacity - Google Patents
Peptide having zirconia-binding capacity Download PDFInfo
- Publication number
- US20170296695A1 US20170296695A1 US15/504,035 US201615504035A US2017296695A1 US 20170296695 A1 US20170296695 A1 US 20170296695A1 US 201615504035 A US201615504035 A US 201615504035A US 2017296695 A1 US2017296695 A1 US 2017296695A1
- Authority
- US
- United States
- Prior art keywords
- zirconia
- peptide
- physiologically active
- binding peptide
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 title claims abstract description 212
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 112
- 239000000863 peptide conjugate Substances 0.000 claims abstract description 12
- 239000007943 implant Substances 0.000 claims description 45
- 210000000988 bone and bone Anatomy 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 239000012620 biological material Substances 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 8
- 230000017423 tissue regeneration Effects 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 229920005615 natural polymer Polymers 0.000 claims description 5
- 229920001059 synthetic polymer Polymers 0.000 claims description 5
- 239000000783 alginic acid Substances 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 claims description 4
- 229910001928 zirconium oxide Inorganic materials 0.000 claims description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 3
- 238000007385 chemical modification Methods 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 230000008467 tissue growth Effects 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 108091023040 Transcription factor Proteins 0.000 claims description 2
- 102000040945 Transcription factor Human genes 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 230000021164 cell adhesion Effects 0.000 claims description 2
- 230000012292 cell migration Effects 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- -1 propylene glycol alginic acid Chemical class 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000013543 active substance Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 230000001172 regenerating effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 238000002823 phage display Methods 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 229960002685 biotin Drugs 0.000 description 10
- 239000011616 biotin Substances 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 238000010883 osseointegration Methods 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000004793 Polystyrene Substances 0.000 description 6
- 229910052586 apatite Inorganic materials 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 238000004091 panning Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000562 conjugate Substances 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000004053 dental implant Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000009818 osteogenic differentiation Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OYRSKXCXEFLTEY-UHFFFAOYSA-N 1-[2-[2-[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxy]ethoxy]ethyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCOCCOCCOCCN1C(=O)C=CC1=O OYRSKXCXEFLTEY-UHFFFAOYSA-N 0.000 description 1
- WXXSHAKLDCERGU-UHFFFAOYSA-N 1-[4-(2,5-dioxopyrrol-1-yl)butyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCCCN1C(=O)C=CC1=O WXXSHAKLDCERGU-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 241000244038 Brugia malayi Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108010005636 polypeptide C Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/306—Other specific inorganic materials not covered by A61L27/303 - A61L27/32
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/12—Materials or treatment for tissue regeneration for dental implants or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Definitions
- the present invention relates to a peptide that binds specifically to the surface of zirconia, and more particularly, to a peptide conjugate obtained by linking a functional drug to the peptide so as to enable the drug to be securely fixed to the surface of zirconia to thereby maintain the activity of the drug over a long period of time.
- Implant materials to be implanted in vivo are widely used as artificial teeth capable of replacing missing teeth to restore the masticatory function of some or all of the missing teeth.
- the success rate and long-term prognosis of implant treatment are influenced by the bone quantity and quality of the implant site in the patient, and depend on the stability of the implant.
- the stability of the implant can be divided into physical fixation that is obtained when the implant is brought into contact with the surrounding bone upon implant placement and biological fixation that results from the formation of new bone tissue around the implant and the occurrence of osseointegration in the surrounding bone after placement of the implant (Guideline for Evaluation of Zirconia Materials, the Korea Food & Drug Administration, 2011).
- the stability of the implant is reduced while bone resorption for forming new bone in the existing bone occurs.
- the stability of the implant gradually increases again by osseointegration between the implant and the alveolar bone.
- early failure of the implant may occur, and if a load is applied to the implant having low initial stability, delayed osseointegration may be caused by micro-motion.
- the present inventors have made extensive efforts to solve the above-described problems occurring in the prior art, and as a result, have identified a short peptide sequence having a strong binding affinity for the surface of an implant, and have found that the peptide easily binds to the surface of a zirconia implant and is maintained in a stable state, thereby completing the present invention.
- the present invention provides a zirconia-binding peptide represented by the amino acid sequence of SEQ ID NO: 1.
- the present invention also provides a peptide conjugate comprising a physiologically active peptide or physiologically active protein linked to the above-described zirconia-binding peptide.
- the present invention also provides a biomaterial comprising the above-described zirconia-binding peptide or the above-described peptide conjugate.
- FIG. 1 shows the results of a binding assay performed using an avidin-biotin complex to measure the binding affinities of a zirconia-binding peptide sequence and a sequence of Comparative Example 1.
- FIG. 2 shows the results of a binding assay performed using an avidin-biotin complex to measure the binding affinities of a zirconia-binding peptide sequence and sequences of Comparative Examples 2 and 3.
- FIG. 3 shows the results of a binding assay performed using an avidin-biotin complex to measure the maximum amount of zirconia-binding peptide sequence bound to the zirconia disc surface.
- a peptide linker capable of binding to the surface of a zirconia implant without chemical modification a peptide sequence having a binding affinity for an implant made of zirconia was identified by a phage display technique, and it was found that the peptide can be present on the zirconia surface in a stable state.
- the present invention is directed to a zirconia-binding peptide represented by the amino acid sequence of SEQ ID NO: 1.
- the zirconia-binding peptide preferably binds to zirconia, which is used as a biomaterial, without chemical modification, but is not limited thereto.
- the present invention is directed to a peptide conjugate comprising a physiologically active peptide or physiologically active protein linked to the zirconia-binding peptide.
- the conjugate of the zirconia-binding peptide and the physiologically active peptide may be chemically synthesized using a peptide synthesizer.
- a physiologically active domain may be chemically linked to the C- or N-terminus of the zirconia-binding peptide, thereby synthesizing a zirconia binding peptide-physiologically active peptide (e.g., osteogenic differentiation-inducing sequence) conjugate consisting of N terminus-zirconia binding peptide-physiologically active domain-C terminus or N terminus-physiologically active domain-zirconia binding peptide-C terminus.
- a zirconia binding peptide-physiologically active peptide e.g., osteogenic differentiation-inducing sequence
- the physiologically active domain which is a peptide is a substance that has osteogenic differentiation-inducing activity or anti-inflammatory activity required for implant placement and that regulates gene expression and physiological function in vitro or in vivo.
- This physiologically active domain which is a peptide may act as a controlling agent when a substance that is involved in functional regulation in vivo is deficient or when abnormal pathology caused by excessive secretion appears. It may be an L- or D-form in view of its stability in vivo.
- the physiologically active peptide is preferably selected from the group consisting of anti-inflammatory, anti-microbial, cell adhesion, bone tissue regeneration, and cell migration functional peptides, but is not limited thereto.
- the physiologically active protein is preferably selected from the group consisting of a tissue regeneration factor, a tissue growth factor, an intracellular transcription factor, an extracellular matrix proteins, and an anti-inflammatory protein, but is not limited thereto.
- a conjugate of the zirconia-binding peptide with a physiologically active peptide or a low-molecular substance can be formed by inducing chemical bonding using a crosslinking agent. If chemical bonding is induced using a crosslinking agent, the conjugate will be easily formed by the crosslinking agent, because the N-terminus of the zirconia-binding peptide has a free amino group.
- Examples of a cross-linking agent that can be used in the present invention include, but not limited to, 1,4-bis-maleimidobutane (BMB), 1,11-bismaleimidotetraethyleneglycol (BM[PEO]4), 1-ethyl-3-[3-dimethyl aminopropyl] carbodiimide hydrochloride (EDC), succinimidyl-4-[N-maleimidomethylcyclohexane-1-carboxy-[6-amidocaproate]] (SMCC) and its sulfonate (sulfo-SMCC), succimidyl 6-[3-(2-pyridyldithio)-ropionamido] hexanoate (SPDP) and its sulfonate (sulfo-SPDP), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) and its sulfonate (sulfo-MBS), and succimi
- the present invention is directed to a biomaterial comprising the zirconia-binding peptide or the peptide conjugate.
- the biomaterial is preferably an implant for in-vivo transplantation, which is made of a metal whose surface is coated with zirconia, a natural polymer, a synthetic polymer, and zirconia, but is not limited thereto.
- zirconia is preferably a tetragonal material obtained by adding 3-5 wt % of a stabilizer to pure zirconium oxide, but is not limited thereto.
- the natural polymer is preferably any one selected from the group consisting of collagen, alginic acid, propylene glycol alginic acid, chondroitin sulfate, and chitosan, but is not limited thereto.
- the synthetic polymer is preferably any one selected from the group consisting of polylacticglycolic acid, poloxamer, and propylene glycol, but is not limited thereto.
- a physiologically active substance can be covalently bonded with the peptide without inducing chemical bonding so that it can be present in a stable state while the activity thereof can be maintained. Namely, the migration, proliferation and differentiation of bone tissue regeneration-associated cells around the implant will be promoted, and eventually an efficient tissue regeneration effect can occur within a short time so that the treatment time can be shortened. In addition, side effects on the whole body or other tissues, which can be induced due to an unstable bond on the implant surface, can be reduced. Thus, the implant is useful for surgical regenerative treatment.
- the term “implant” refers to a surgical material or procedure that is used to implant a biocompatible material into a defective area by an additional surgical operation such as bone grafting or distraction osteogenesis to thereby restore the function of the defective area.
- the defective area enters a regular regeneration stage after osseointegration that is the physiological, morphological and direct bonding of the placed implant body surface to the surrounding tissue whose normal function is maintained.
- zirconia generally refers to zirconium oxide (ZrO 2 ). Zirconia has advantages in that it has good biocompatibility and can induce high osseointegration after initial implant placement, because it increases calcium ions through ion exchange and increases cellular mobility to thereby increase the adhesion of the zirconia to bone.
- a new phage display technique named “subtractive panning”, was additionally used to exclude the possibility of selecting a sequence that binds materials other than the zirconia disc surface.
- the term “subtractive panning” refers to a phage display technique which may be used to identify a sequence that binds to a specific material without binding to other specific materials.
- a phage library is applied to a material that does not want to bind, and unbound phages are recovered, after which the phages are applied to a material that wishes to bind, and then unbound phages are discarded, and bound phages are recovered (Munirathinam, Gnanasekar et. al., Novel Phage Display-Based Subtrative Screening To Identify Vaccine Candidates of Brugia malayi, Infect Immun., 72:4707-4715, 2004).
- a phage display technique was used to identify a specific peptide sequence that binds to the zirconia disc surface. M13 phages labeled with a random peptide library with high diversity and complexity were applied to the zirconia disc surface, after which unbound phages were washed out, and bound phages were recovered. These procedures were repeated several times. A subtractive panning procedure was additionally used, and the DNA sequence of a peptide bound to the finally obtained phage was analyzed, thereby identifying a zirconia-binding peptide sequence. The subtractive panning is a new phage display technique which may be used to identify a sequence that binds to a specific material without binding to other specific materials.
- polystyrene plate wells were used to identify a zirconia-binding peptide through phage display, and thus this technique was applied to exclude sequences that bind to the polystyrene plate in addition to the zirconia disc surface.
- the resulting phages were amplified again and added to empty wells of a polystyrene plate, and then phages not bound to the well surface were recovered. Then, the recovered phages not bound to the polystyrene plate were bound once more to the zirconia disc surface, and then washed strongly with washing buffer, and only the remaining bound phages were finally recovered.
- the phage display kit used was Ph.D.-12 Phage Display Kit purchased from New England Biolabs (USA).
- the kit contains phages labeled with a random peptide library consisting of 12 amino acids, 16 final clones screened using the kit were sent to Cosmogenetech Co., Ltd. (Korea) in an E. coli culture state to analyze the sequences thereof.
- Peptides represented by SEQ ID NOs: 1 to 4 were synthesized from the C-terminus to the N-terminus by an F-moc solid-phase synthesis method using a synthesizer. Specifically, the peptides were synthesized using Rink resin (0.075 mmol/g, 100 ⁇ 200 mesh, 1% DVB crosslinking) having Fmoc-(9-fluorenylmethoxycarbonyl) as a blocking group linked thereto. 50 mg of Rink resin was placed in a synthesizer, and then swollen with DMF, after which the Fmoc-group was removed using a 20% piperidine/DMF solution.
- Rink resin 0.075 mmol/g, 100 ⁇ 200 mesh, 1% DVB crosslinking
- a 0.5M amino acid solution (solvent: dimethylformamide, DMF) according to the sequence from the C-terminus to the N-terminus, 1.0M DIPEA (dimethylformamide & N-methylpyrrolidone, DMF & NMP) and 0.5M HBTU (solvent: dimethylformamide, DMF) were added to the resin in amounts of 5, 10 and 5 equivalents, respectively, and allowed to react for 1-2 hours under a nitrogen atmosphere. After completion of each of the deprotection and coupling steps, the resin was washed twice with DMF and NMP. Even after coupling of the final amino acid, the resin was deprotected to remove the Fmoc-group.
- Each of the synthesized peptides was cut from the resin, washed, freeze-dried, and then purified by liquid chromatography. The molecular weights of the purified peptides were measured by mass spectrometry.
- VSAAGTKASPAV Zr-BPC
- SEQ ID NO: 2 Zr-BPC
- phenylalanine at 2 nd and 9 th positions, tryptophan at 5 th position and proline at 10 th position from the C-terminus in the sequence of SEQ ID NO: 1 were synthesized by an F-moc solid-phase synthesis method using a peptide synthesizer.
- Comparative Example 2 Synthesis of Peptide that Binds to the Surface of Empty Well Containing No Zirconia Disc
- Example 1 and Comparative Examples 1 and 2 the peptides were labeled with biotin.
- Each of the synthesized peptide domains was biotinylated using EZ-Link Sulfo-NHS-Biotin (Pierce Biotechnology, USA) according to the manufacturer's instruction, and unbound byproducts were removed by ultrafiltration that is a membrane separation method based on a pressure difference.
- the molecular weights of the synthesized products were measured by mass spectrometry.
- the synthesized products were analyzed and purified by reverse phase liquid chromatography.
- a C 18 column having a diameter of 4.6 mm was used, and 0.1% TFA/H 2 O and 0.092% TFA/acetonitrile were flushed onto the column at a rate of 1 ml/min with a gradient of 0-60% for 30 minutes.
- the wavelength of the UV detector used was 220 nm.
- a column having a diameter of 2.2 cm was used, and a flow rate of 20 ml/min and the solvent and detection wavelength as described above were used. Only the biotin-labeled peptide fraction was collected, and concentrated using a rotary evaporator to remove the solvent, followed by freeze-drying.
- a binding assay using an avidin-biotin complex was performed. Specifically, one zirconia disc was placed in each well of a 12-well polystyrene plate, and then blocked with a blocking buffer (0.1 M NaHCO 3 (pH 8.6), 5 mg/ml BSA, 0.02% NaN 3 (optional), filter sterilize) for at least one hour.
- a blocking buffer 0.1 M NaHCO 3 (pH 8.6), 5 mg/ml BSA, 0.02% NaN 3 (optional), filter sterilize
- each zirconia disc was strongly washed six times or more with a washing buffer (TBS+0.1% [v/v] Tween-20), after which 200 ⁇ l of each of the zirconia-binding peptide Zr-BP (SEQ ID NO: 1) of Example 1 and the peptides Zr-BPC (SEQ ID NO: 2), PL1 (SEQ ID NO: 3) and PL2 (SEQ ID NO: 4) of Comparative Examples 1 and 2, which were biotin-labeled, synthesized, separated and purified in Example 3-1, was dispensed to the surface of each zirconia disc at a concentration ranging from 100 nM to 1 ⁇ M.
- a washing buffer TBS+0.1% [v/v] Tween-20
- Each zirconia disc was incubated at room temperature for 15 hours, and then washed strongly with a washing buffer, and 200 ⁇ l of a 1:500 dilution of ExtrAvidin-peroxidase (Cat. #E2886, Sigma-Aldrich, USA) in a blocking buffer was dispensed to the surface of each zirconia disc.
- Each zirconia disc was incubated at room temperature for 1 hour, and then washed strongly with a washing buffer, after which 200 ⁇ l of a substrate solution (2,2′-AZINO-BIS, Cat.
- each zirconia disc was dispensed to the surface of each zirconia disc and allowed to react at room temperature for 20 minutes so as to develop color.
- Each zirconia disc was treated with 200 ⁇ l of 1% SDS solution to stop the reaction, and the absorbance at 405 nm was measured.
- zirconia-binding peptide Zr-BP SEQ ID NO: 1
- a binding assay using a avidin-biotin complex was performed. Specifically, one zirconia disc was placed in each well of a 12-well polystyrene plate, and then blocked with a blocking buffer (0.1 M NaHCO 3 (pH 8.6), 5 mg/ml BSA, 0.02% NaN 3 (optional), filter sterilize) for at least one hour.
- a blocking buffer 0.1 M NaHCO 3 (pH 8.6), 5 mg/ml BSA, 0.02% NaN 3 (optional), filter sterilize
- each zirconia disc was strongly washed six times or more with a washing buffer (TBS+0.1% [v/v] Tween-20), after which 200 ⁇ l of each of the zirconia-binding peptide Zr-BP (SEQ ID NO: 1) of Example 1 and the peptides Zr-BPC (SEQ ID NO: 2), PL1 (SEQ ID NO: 3) and PL2 (SEQ ID NO: 4) of Comparative Examples 1 and 2, which were biotin-labeled, synthesized, separated and purified in Example 3-1, was dispensed to the surface of each zirconia disc at a concentration ranging from 100 nM to 40 mM.
- a washing buffer TBS+0.1% [v/v] Tween-20
- Each zirconia disc was incubated at room temperature for 15 hours, and then washed strongly with a washing buffer, and 200 ⁇ l of a 1:500 dilution of ExtrAvidin-peroxidase (Cat. #E2886, Sigma-Aldrich, USA) in a blocking buffer was dispensed to the surface of each zirconia disc.
- Each zirconia disc was incubated at room temperature for 1 hour, and then washed strongly with a washing buffer, after which 200 ⁇ l of a substrate solution (2,2′-AZINO-BIS, Cat.
- each zirconia disc was dispensed to the surface of each zirconia disc and allowed to react at room temperature for 20 minutes so as to develop color.
- Each zirconia disc was treated with 200 ⁇ l of 1% SDS solution to stop the reaction, and the absorbance at 405 nm was measured.
- the zirconia-binding peptide Zr-BP (SEQ ID NO: 1) showed the maximum absorbance value at a concentration of 2 mM. Absorbance changes appearing at a concentration of 10 mM or higher are believed to be false-negative results that can be explained by the high-dose hook effect.
- the maximum amount of zirconia-binding peptide bound to the surface of one zirconia disc is 622.8 ⁇ g.
- the diameter of the zirconia disc is 15.5 mm, about 3.3 ⁇ g of the zirconia-binding peptide can be fixed per mm 2 of the zirconia disc surface.
- the zirconia-binding peptide according to the present invention can be securely fixed to the surface of zirconia so that the activity of a physiologically active substance introduced into the peptide can be maintained on the zirconia surface over a long period of time.
- the zirconia-binding peptide is useful for surgical regenerative treatment.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Animal Behavior & Ethology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
- The present invention relates to a peptide that binds specifically to the surface of zirconia, and more particularly, to a peptide conjugate obtained by linking a functional drug to the peptide so as to enable the drug to be securely fixed to the surface of zirconia to thereby maintain the activity of the drug over a long period of time.
- Implant materials to be implanted in vivo, particularly dental implant materials, are widely used as artificial teeth capable of replacing missing teeth to restore the masticatory function of some or all of the missing teeth. The success rate and long-term prognosis of implant treatment are influenced by the bone quantity and quality of the implant site in the patient, and depend on the stability of the implant. The stability of the implant can be divided into physical fixation that is obtained when the implant is brought into contact with the surrounding bone upon implant placement and biological fixation that results from the formation of new bone tissue around the implant and the occurrence of osseointegration in the surrounding bone after placement of the implant (Guideline for Evaluation of Zirconia Materials, the Korea Food & Drug Administration, 2011).
- When an implant is placed in the alveolar bone of an adult patient, the stability of the implant is reduced while bone resorption for forming new bone in the existing bone occurs. However, while new bone is formed around the implant, the stability of the implant gradually increases again by osseointegration between the implant and the alveolar bone. However, in the case of elderly patients in whom it is difficult to ensure initial implant stability important for osseointegration, due to insufficient bone quantity or quality, early failure of the implant may occur, and if a load is applied to the implant having low initial stability, delayed osseointegration may be caused by micro-motion. Until now, to overcome such shortcomings, it has been attempted to increase initial implant stability by changing the length or diameter of the implant itself or treating the surface of the implant to increase the ability of the implant to adhere to osteocytes. However, it is still difficult to ensure initial implant stability after implant placement by such physical changes (Nakamura K et al., International Journal of Prosthodontics 23:299-309, 2010).
- Thus, in the case of not only elderly patients having insufficient bone quality and quantity, but also general adult patients, it is essential to apply biological factors in order to promote initial osseointegration after implant placement and shorten the treatment period. Until now, a product obtained by chemically immobilizing a physiologically active substance on the surface of a dental implant has not yet been commercialized. However, in the case of apatite which is used as a synthetic material to increase bone quantity during implant placement, studies have been conducted on the use of apatite together with a physiologically active material such as extracellular matrix protein, tissue growth factor or bone morphogenetic protein. In addition, products such as GEM21S (containing PDGF), INFUSE (containing BMP-2) and the like, obtained by applying apatite together with a physiologically active substance or coating the surface of apatite with a physiologically active substance, have been developed. However, there are problems in that, after these products are implanted in vivo, the physiologically active substance is not securely fixed to the surface of the apatite material and is easily released from the surface of the apatite material so as to be degraded by exposure to systemic blood, and thus the physiological activity of the physiologically active substance can be reduced and the physiologically active substance can cause side effects in tissues other than the target tissue. For this reason, for tissue regeneration by an implant, it is required that a physiologically active substance be securely fixed to the surface of the implant biomaterial so that the effective activity thereof can be maintained over a long period of time (KR 10-1213355).
- Accordingly, the present inventors have made extensive efforts to solve the above-described problems occurring in the prior art, and as a result, have identified a short peptide sequence having a strong binding affinity for the surface of an implant, and have found that the peptide easily binds to the surface of a zirconia implant and is maintained in a stable state, thereby completing the present invention.
- It is an object of the present invention to provide a zirconia-binding peptide represented by the amino acid sequence of SEQ ID NO: 1, a peptide conjugate comprising a physiologically active peptide or physiologically active protein linked to the zirconia-binding peptide, and a biomaterial comprising the zirconia-binding peptide or the peptide conjugate.
- To achieve the above objects, the present invention provides a zirconia-binding peptide represented by the amino acid sequence of SEQ ID NO: 1.
- The present invention also provides a peptide conjugate comprising a physiologically active peptide or physiologically active protein linked to the above-described zirconia-binding peptide.
- The present invention also provides a biomaterial comprising the above-described zirconia-binding peptide or the above-described peptide conjugate.
-
FIG. 1 shows the results of a binding assay performed using an avidin-biotin complex to measure the binding affinities of a zirconia-binding peptide sequence and a sequence of Comparative Example 1. -
FIG. 2 shows the results of a binding assay performed using an avidin-biotin complex to measure the binding affinities of a zirconia-binding peptide sequence and sequences of Comparative Examples 2 and 3. -
FIG. 3 shows the results of a binding assay performed using an avidin-biotin complex to measure the maximum amount of zirconia-binding peptide sequence bound to the zirconia disc surface. - Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Generally, the nomenclatures used herein are those well known and commonly employed in the art.
- In the present invention, in order to securely fix a physiologically active substance to enable the activity thereof to be maintained over a long period of time, by use of a peptide linker capable of binding to the surface of a zirconia implant without chemical modification, a peptide sequence having a binding affinity for an implant made of zirconia was identified by a phage display technique, and it was found that the peptide can be present on the zirconia surface in a stable state.
- In one aspect, the present invention is directed to a zirconia-binding peptide represented by the amino acid sequence of SEQ ID NO: 1.
- In the present invention, the zirconia-binding peptide preferably binds to zirconia, which is used as a biomaterial, without chemical modification, but is not limited thereto.
- In another aspect, the present invention is directed to a peptide conjugate comprising a physiologically active peptide or physiologically active protein linked to the zirconia-binding peptide.
- In the present invention, the conjugate of the zirconia-binding peptide and the physiologically active peptide may be chemically synthesized using a peptide synthesizer. Specifically, a physiologically active domain may be chemically linked to the C- or N-terminus of the zirconia-binding peptide, thereby synthesizing a zirconia binding peptide-physiologically active peptide (e.g., osteogenic differentiation-inducing sequence) conjugate consisting of N terminus-zirconia binding peptide-physiologically active domain-C terminus or N terminus-physiologically active domain-zirconia binding peptide-C terminus.
- The physiologically active domain which is a peptide is a substance that has osteogenic differentiation-inducing activity or anti-inflammatory activity required for implant placement and that regulates gene expression and physiological function in vitro or in vivo. This physiologically active domain which is a peptide may act as a controlling agent when a substance that is involved in functional regulation in vivo is deficient or when abnormal pathology caused by excessive secretion appears. It may be an L- or D-form in view of its stability in vivo.
- In the present invention, the physiologically active peptide is preferably selected from the group consisting of anti-inflammatory, anti-microbial, cell adhesion, bone tissue regeneration, and cell migration functional peptides, but is not limited thereto.
- In the present invention, the physiologically active protein is preferably selected from the group consisting of a tissue regeneration factor, a tissue growth factor, an intracellular transcription factor, an extracellular matrix proteins, and an anti-inflammatory protein, but is not limited thereto.
- In the present invention, a conjugate of the zirconia-binding peptide with a physiologically active peptide or a low-molecular substance can be formed by inducing chemical bonding using a crosslinking agent. If chemical bonding is induced using a crosslinking agent, the conjugate will be easily formed by the crosslinking agent, because the N-terminus of the zirconia-binding peptide has a free amino group.
- Examples of a cross-linking agent that can be used in the present invention include, but not limited to, 1,4-bis-maleimidobutane (BMB), 1,11-bismaleimidotetraethyleneglycol (BM[PEO]4), 1-ethyl-3-[3-dimethyl aminopropyl] carbodiimide hydrochloride (EDC), succinimidyl-4-[N-maleimidomethylcyclohexane-1-carboxy-[6-amidocaproate]] (SMCC) and its sulfonate (sulfo-SMCC), succimidyl 6-[3-(2-pyridyldithio)-ropionamido] hexanoate (SPDP) and its sulfonate (sulfo-SPDP), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) and its sulfonate (sulfo-MBS), and succimidyl [4-(p-maleimidophenyl) butyrate] (SMPB) and its sulfonate (sulfo-SMPB).
- In another aspect, the present invention is directed to a biomaterial comprising the zirconia-binding peptide or the peptide conjugate.
- In the present invention, the biomaterial is preferably an implant for in-vivo transplantation, which is made of a metal whose surface is coated with zirconia, a natural polymer, a synthetic polymer, and zirconia, but is not limited thereto.
- In the present invention, zirconia is preferably a tetragonal material obtained by adding 3-5 wt % of a stabilizer to pure zirconium oxide, but is not limited thereto.
- In the present invention, the natural polymer is preferably any one selected from the group consisting of collagen, alginic acid, propylene glycol alginic acid, chondroitin sulfate, and chitosan, but is not limited thereto. In addition, the synthetic polymer is preferably any one selected from the group consisting of polylacticglycolic acid, poloxamer, and propylene glycol, but is not limited thereto.
- When a zirconia-coated metal, a natural polymer, a synthetic polymer and a dental or orthopedic implant are implanted in vivo, a physiologically active substance can be covalently bonded with the peptide without inducing chemical bonding so that it can be present in a stable state while the activity thereof can be maintained. Namely, the migration, proliferation and differentiation of bone tissue regeneration-associated cells around the implant will be promoted, and eventually an efficient tissue regeneration effect can occur within a short time so that the treatment time can be shortened. In addition, side effects on the whole body or other tissues, which can be induced due to an unstable bond on the implant surface, can be reduced. Thus, the implant is useful for surgical regenerative treatment.
- As used herein, the term “implant” refers to a surgical material or procedure that is used to implant a biocompatible material into a defective area by an additional surgical operation such as bone grafting or distraction osteogenesis to thereby restore the function of the defective area. The defective area enters a regular regeneration stage after osseointegration that is the physiological, morphological and direct bonding of the placed implant body surface to the surrounding tissue whose normal function is maintained.
- As used herein, the term “zirconia” generally refers to zirconium oxide (ZrO2). Zirconia has advantages in that it has good biocompatibility and can induce high osseointegration after initial implant placement, because it increases calcium ions through ion exchange and increases cellular mobility to thereby increase the adhesion of the zirconia to bone.
- Pure titanium that is currently widely used as an implant material has a problem in that it can show metal allergic reactions, or has a disadvantage in that bacteria are highly likely to adhere thereto. For this reason, in the case of patients with reduced immunity, the application of an implant made of another biocompatible material should be taken into consideration. In recent years, it was reported that a ceramic implant made of zirconia that is used as a substituent for titanium has excellent biocompatibility, shows the highest mechanical strength among ceramic materials, can resist rapid temperature changes, and has excellent aesthetic properties. Due to such advantages, zirconia is widely used as a material for artificial teeth.
- In the present invention, a new phage display technique, named “subtractive panning”, was additionally used to exclude the possibility of selecting a sequence that binds materials other than the zirconia disc surface.
- As used herein, the term “subtractive panning” refers to a phage display technique which may be used to identify a sequence that binds to a specific material without binding to other specific materials. In the subtractive panning technique, a phage library is applied to a material that does not want to bind, and unbound phages are recovered, after which the phages are applied to a material that wishes to bind, and then unbound phages are discarded, and bound phages are recovered (Munirathinam, Gnanasekar et. al., Novel Phage Display-Based Subtrative Screening To Identify Vaccine Candidates of Brugia malayi, Infect Immun., 72:4707-4715, 2004).
- Hereinafter, the present invention will be described in further detail with reference to examples. It will be obvious to a person having ordinary skill in the art that these examples are illustrative purposes only and are not to be construed to limit the scope of the present invention.
- To identify a specific peptide sequence that binds to the zirconia disc surface, a phage display technique was used. M13 phages labeled with a random peptide library with high diversity and complexity were applied to the zirconia disc surface, after which unbound phages were washed out, and bound phages were recovered. These procedures were repeated several times. A subtractive panning procedure was additionally used, and the DNA sequence of a peptide bound to the finally obtained phage was analyzed, thereby identifying a zirconia-binding peptide sequence. The subtractive panning is a new phage display technique which may be used to identify a sequence that binds to a specific material without binding to other specific materials.
- In this Example, polystyrene plate wells were used to identify a zirconia-binding peptide through phage display, and thus this technique was applied to exclude sequences that bind to the polystyrene plate in addition to the zirconia disc surface.
-
TABLE 1 Amino acid Clone DNA sequence sequence #1 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #2 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #3 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #4 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #5 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #6 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #7 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #8 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #9 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #10 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #11 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #12 No insert N/A #13 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #14 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #15 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ #16 5′-GTG AGT CCG TTT GGT ACT VSPFGTKWSPFV AAG TGG TCT CCG TTT GTT-3′ It was revealed that clone #12 had no insert by DNA sequencing. However, other fifteen clones indicate identical sequences, VSPFGTKWSPFV - After completion of repeated cycles of the above-mentioned conventional phage display, the resulting phages were amplified again and added to empty wells of a polystyrene plate, and then phages not bound to the well surface were recovered. Then, the recovered phages not bound to the polystyrene plate were bound once more to the zirconia disc surface, and then washed strongly with washing buffer, and only the remaining bound phages were finally recovered.
- The phage display kit used was Ph.D.-12 Phage Display Kit purchased from New England Biolabs (USA). The kit contains phages labeled with a random peptide library consisting of 12 amino acids, 16 final clones screened using the kit were sent to Cosmogenetech Co., Ltd. (Korea) in an E. coli culture state to analyze the sequences thereof.
- As a result, as can be seen in Table 1 above, 15 clones had the same DNA sequence, and the final peptide sequence Zr-BP (VSPFGTKWSPFV; SEQ ID NO: 1) consisting of 12 amino acid residues could be obtained by translation of the DNA sequence. Because the peptide sequence is highly likely to be a specific sequence that binds to the zirconia disc surface, the peptide sequence was selected as a specific peptide sequence candidate that binds to the zirconia disc surface.
- Peptides represented by SEQ ID NOs: 1 to 4 were synthesized from the C-terminus to the N-terminus by an F-moc solid-phase synthesis method using a synthesizer. Specifically, the peptides were synthesized using Rink resin (0.075 mmol/g, 100˜200 mesh, 1% DVB crosslinking) having Fmoc-(9-fluorenylmethoxycarbonyl) as a blocking group linked thereto. 50 mg of Rink resin was placed in a synthesizer, and then swollen with DMF, after which the Fmoc-group was removed using a 20% piperidine/DMF solution. A 0.5M amino acid solution (solvent: dimethylformamide, DMF) according to the sequence from the C-terminus to the N-terminus, 1.0M DIPEA (dimethylformamide & N-methylpyrrolidone, DMF & NMP) and 0.5M HBTU (solvent: dimethylformamide, DMF) were added to the resin in amounts of 5, 10 and 5 equivalents, respectively, and allowed to react for 1-2 hours under a nitrogen atmosphere. After completion of each of the deprotection and coupling steps, the resin was washed twice with DMF and NMP. Even after coupling of the final amino acid, the resin was deprotected to remove the Fmoc-group.
- Synthesis of the peptides was confirmed using a ninhydrin test method. The synthesized and tested resin was dried with tetrahydrofuran (THF) or dichloromethane (DCM), and then a trifluoroacetic acid (TFA) cleavage cocktail was added to the resin in an amount of 20 ml per g of the resin, followed by shaking for 3 hours. Next, the cocktail containing the resin and peptide dissolved therein was separated by filtration. Cold ether was added after removing the filtered out solution using a rotary evaporator or an excess amount of cold ether was added directly to the TFA cocktail solution containing the peptide dissolved therein, so as to crystallize the peptide in a solid phase. The crystallized peptide was isolated by centrifugation. At this time, the TFA cocktail was completely removed by washing several times with ether and a centrifugation process. The peptides thus obtained were dissolved in distilled water and freeze-dried.
- Each of the synthesized peptides was cut from the resin, washed, freeze-dried, and then purified by liquid chromatography. The molecular weights of the purified peptides were measured by mass spectrometry.
- Zr-BPC (VSAAGTKASPAV; SEQ ID NO: 2) wherein phenylalanine at 2nd and 9th positions, tryptophan at 5th position and proline at 10th position from the C-terminus in the sequence of SEQ ID NO: 1 are substituted with alanine was synthesized by an F-moc solid-phase synthesis method using a peptide synthesizer.
- Through phage display, a 12-amino acid peptide sequence that binds to the surface of an empty well containing no zirconia disc was screened. Four clones were sent to Cosmogenetech Co., Ltd. (Korea) in an E. coli culture state to analyze the sequences thereof.
- As a result, as shown in Table 2 below, two of the four clones had specific DNA sequences. The two DNA sequences were translated to obtain peptides PL1 (IGNSFSFPAVYR; SEQ ID NO: 3) and PL2 (LRLDVDRAISLL; SEQ ID NO: 4), each consisting of 12 amino acids. The peptides were synthesized by an F-moc solid-phase synthesis method using a peptide synthesizer.
-
TABLE 2 Amino acid Clone DNA sequence sequence #1 No insert N/A #2 5′-ATT GGG AAT AGT TTT TCT IGNSFSFPAVYR TTT CCT GCG GTT TAT AGG-3′ #3 5′-TTG CGG TTG GAT GTT GAT LRLDVDRAISLL AGG GCT ATT AGT TTG TTG-3′ #4 No insert N/A It was revealed that clone #1 and #4 had no insert by DNA sequencing. - 3-1: Synthesis of Zirconia-Binding Peptide Labeled with Biotin
- In order to examine the binding affinities of the peptides synthesized in Example 1 and Comparative Examples 1 and 2, the peptides were labeled with biotin. Each of the synthesized peptide domains was biotinylated using EZ-Link Sulfo-NHS-Biotin (Pierce Biotechnology, USA) according to the manufacturer's instruction, and unbound byproducts were removed by ultrafiltration that is a membrane separation method based on a pressure difference. The molecular weights of the synthesized products were measured by mass spectrometry. The synthesized products were analyzed and purified by reverse phase liquid chromatography. For analysis, a C18 column having a diameter of 4.6 mm was used, and 0.1% TFA/H2O and 0.092% TFA/acetonitrile were flushed onto the column at a rate of 1 ml/min with a gradient of 0-60% for 30 minutes. The wavelength of the UV detector used was 220 nm. For purification, a column having a diameter of 2.2 cm was used, and a flow rate of 20 ml/min and the solvent and detection wavelength as described above were used. Only the biotin-labeled peptide fraction was collected, and concentrated using a rotary evaporator to remove the solvent, followed by freeze-drying.
- 3-2: Measurement of Binding Affinity of Zirconia-Binding Peptide
- To measure the binding affinity of the zirconia-binding peptide, a binding assay using an avidin-biotin complex was performed. Specifically, one zirconia disc was placed in each well of a 12-well polystyrene plate, and then blocked with a blocking buffer (0.1 M NaHCO3 (pH 8.6), 5 mg/ml BSA, 0.02% NaN3 (optional), filter sterilize) for at least one hour. Next, the blocking buffer was discarded, and each zirconia disc was strongly washed six times or more with a washing buffer (TBS+0.1% [v/v] Tween-20), after which 200 μl of each of the zirconia-binding peptide Zr-BP (SEQ ID NO: 1) of Example 1 and the peptides Zr-BPC (SEQ ID NO: 2), PL1 (SEQ ID NO: 3) and PL2 (SEQ ID NO: 4) of Comparative Examples 1 and 2, which were biotin-labeled, synthesized, separated and purified in Example 3-1, was dispensed to the surface of each zirconia disc at a concentration ranging from 100 nM to 1 μM. Each zirconia disc was incubated at room temperature for 15 hours, and then washed strongly with a washing buffer, and 200 μl of a 1:500 dilution of ExtrAvidin-peroxidase (Cat. #E2886, Sigma-Aldrich, USA) in a blocking buffer was dispensed to the surface of each zirconia disc. Each zirconia disc was incubated at room temperature for 1 hour, and then washed strongly with a washing buffer, after which 200 μl of a substrate solution (2,2′-AZINO-BIS, Cat. #A3219, Sigma-Aldrich, USA) was dispensed to the surface of each zirconia disc and allowed to react at room temperature for 20 minutes so as to develop color. Each zirconia disc was treated with 200 μl of 1% SDS solution to stop the reaction, and the absorbance at 405 nm was measured.
- As a result, as can be seen in
FIG. 1 , when each zirconia disc was treated with each of the zirconia-binding peptide Zr-BP (SEQ ID NO: 1) of Example 1 and the peptide Zr-BPC (SEQ ID NO: 2) of Comparative Example 1, the absorbance value of the zirconia-binding peptide Zr-BP of Example 1 was higher than that of the peptide Zr-BPC of Comparative Example 1, and this increase in absorbance value was concentration-dependent. This demonstrates that the zirconia-binding peptide sequence is a sequence that binds to the zirconia disc surface in a concentration-dependent manner. In addition, such results suggest that the peptide sequence has a binding motif, although the binding affinity thereof is reduced due to the substitution of some amino acids with alanine. - As shown in
FIG. 2 , when each zirconia disc was treated with each of the zirconia-binding peptide Zr-BP (SEQ ID NO: 1) of Example 1 and the peptides PL1 (SEQ ID NO: 3) and PL2 (SEQ ID NO: 4) of Comparative Example 2, the absorbance value of the zirconia-binding peptide Zr-BP of Example 1 was higher than those of the peptides (PL1 and PL2) of Comparative Example 2, and this increase in absorbance value was concentration-dependent. The peptides (PL1 and PL2) of Comparative Example 2 showed absorbance values independent of the concentration thereof, indicating that the peptide sequences of Comparative Example 2 do not bind to the zirconia disc surface. - To examine the maximum binding amount of the zirconia-binding peptide Zr-BP (SEQ ID NO: 1) per unit area of the zirconia disc surface, a binding assay using a avidin-biotin complex was performed. Specifically, one zirconia disc was placed in each well of a 12-well polystyrene plate, and then blocked with a blocking buffer (0.1 M NaHCO3 (pH 8.6), 5 mg/ml BSA, 0.02% NaN3 (optional), filter sterilize) for at least one hour. Next, the blocking buffer was discarded, and each zirconia disc was strongly washed six times or more with a washing buffer (TBS+0.1% [v/v] Tween-20), after which 200 μl of each of the zirconia-binding peptide Zr-BP (SEQ ID NO: 1) of Example 1 and the peptides Zr-BPC (SEQ ID NO: 2), PL1 (SEQ ID NO: 3) and PL2 (SEQ ID NO: 4) of Comparative Examples 1 and 2, which were biotin-labeled, synthesized, separated and purified in Example 3-1, was dispensed to the surface of each zirconia disc at a concentration ranging from 100 nM to 40 mM. Each zirconia disc was incubated at room temperature for 15 hours, and then washed strongly with a washing buffer, and 200 μl of a 1:500 dilution of ExtrAvidin-peroxidase (Cat. #E2886, Sigma-Aldrich, USA) in a blocking buffer was dispensed to the surface of each zirconia disc. Each zirconia disc was incubated at room temperature for 1 hour, and then washed strongly with a washing buffer, after which 200 μl of a substrate solution (2,2′-AZINO-BIS, Cat. #A3219, Sigma-Aldrich, USA) was dispensed to the surface of each zirconia disc and allowed to react at room temperature for 20 minutes so as to develop color. Each zirconia disc was treated with 200 μl of 1% SDS solution to stop the reaction, and the absorbance at 405 nm was measured.
- As a result, as can be seen in
FIG. 3 , the zirconia-binding peptide Zr-BP (SEQ ID NO: 1) showed the maximum absorbance value at a concentration of 2 mM. Absorbance changes appearing at a concentration of 10 mM or higher are believed to be false-negative results that can be explained by the high-dose hook effect. Based on the back-calculation from the molecular weight and dispensing amount of the zirconia-binding peptide, it can be seen that the maximum amount of zirconia-binding peptide bound to the surface of one zirconia disc is 622.8 μg. Thus, it can be seen that, because the diameter of the zirconia disc is 15.5 mm, about 3.3 μg of the zirconia-binding peptide can be fixed per mm2 of the zirconia disc surface. - The zirconia-binding peptide according to the present invention can be securely fixed to the surface of zirconia so that the activity of a physiologically active substance introduced into the peptide can be maintained on the zirconia surface over a long period of time. Thus, the zirconia-binding peptide is useful for surgical regenerative treatment.
- Although the present invention has been described in detail with reference to the specific features, it will be apparent to those skilled in the art that this description is only for a preferred embodiment and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150048441A KR101681886B1 (en) | 2015-04-06 | 2015-04-06 | Peptide Having Zirconia Binding Affinity |
KR10-2015-0048441 | 2015-04-06 | ||
PCT/KR2016/003505 WO2016163711A1 (en) | 2015-04-06 | 2016-04-05 | Peptide having zirconia-binding capacity |
Publications (2)
Publication Number | Publication Date |
---|---|
US20170296695A1 true US20170296695A1 (en) | 2017-10-19 |
US9801973B1 US9801973B1 (en) | 2017-10-31 |
Family
ID=57073294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/504,035 Active US9801973B1 (en) | 2015-04-06 | 2016-04-05 | Peptide having zirconia-binding capacity |
Country Status (5)
Country | Link |
---|---|
US (1) | US9801973B1 (en) |
EP (1) | EP3281946B1 (en) |
KR (1) | KR101681886B1 (en) |
ES (1) | ES2762949T3 (en) |
WO (1) | WO2016163711A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4841724B2 (en) | 1998-10-09 | 2011-12-21 | ベジェニクス ピーティーワイ リミテッド | Flt4 (VERG-3) as a target for tumor imaging and anti-tumor therapy |
KR101934047B1 (en) | 2016-07-26 | 2018-12-31 | 주식회사 나이벡 | Peptide Having Titanium Binding Affinity |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060068386A1 (en) * | 2002-03-04 | 2006-03-30 | Alexei Slesarev | Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4988076B2 (en) * | 1997-05-22 | 2012-08-01 | マイヤー,ヤールク | Peptide-coated implant and method for preparing the same |
PL337019A1 (en) | 1997-05-22 | 2000-07-31 | Merck Patent Gmbh | Peptide-coated implants and method of obtaining them |
KR100568198B1 (en) | 2004-06-16 | 2006-04-07 | 재단법인서울대학교산학협력재단 | Oligopeptide capable of specific binding to metallic titanium with superior osteointegration |
JP2009007339A (en) | 2007-05-30 | 2009-01-15 | Sanyo Chem Ind Ltd | Adhesive for dental implant |
KR101213355B1 (en) | 2011-12-27 | 2012-12-18 | 오스템임플란트 주식회사 | Dental implant improving initial stability and the method for manufacturing the same |
-
2015
- 2015-04-06 KR KR1020150048441A patent/KR101681886B1/en active IP Right Grant
-
2016
- 2016-04-05 WO PCT/KR2016/003505 patent/WO2016163711A1/en active Application Filing
- 2016-04-05 EP EP16776814.2A patent/EP3281946B1/en active Active
- 2016-04-05 ES ES16776814T patent/ES2762949T3/en active Active
- 2016-04-05 US US15/504,035 patent/US9801973B1/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060068386A1 (en) * | 2002-03-04 | 2006-03-30 | Alexei Slesarev | Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
US9801973B1 (en) | 2017-10-31 |
EP3281946B1 (en) | 2019-10-09 |
EP3281946A4 (en) | 2018-08-29 |
ES2762949T3 (en) | 2020-05-26 |
WO2016163711A1 (en) | 2016-10-13 |
KR101681886B1 (en) | 2016-12-12 |
KR20160119580A (en) | 2016-10-14 |
EP3281946A1 (en) | 2018-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7994277B2 (en) | IFBM's to promote the specific attachment of target analytes to the surface of orthopedic implants | |
US9801973B1 (en) | Peptide having zirconia-binding capacity | |
JP2009538154A (en) | Compositions and methods for promoting attachment of endothelial cell lineage cells to medical devices | |
US8426367B2 (en) | Peptides specific for human blood outgrowth endothelial cells | |
CA2742202A1 (en) | Ifbm's to promote the specific attachment of target analytes to the surface of orthopedic implants | |
US10406264B2 (en) | Peptide having titanium-binding ability |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARK, YOON JEONG;SUH, JIN SOOK;CHUNG, CHONG-PYOUNG;AND OTHERS;REEL/FRAME:041758/0604 Effective date: 20170218 Owner name: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, KOREA, Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARK, YOON JEONG;SUH, JIN SOOK;CHUNG, CHONG-PYOUNG;AND OTHERS;REEL/FRAME:041758/0604 Effective date: 20170218 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |